Nafcillin Inj Rx
Generic Name and Formulations:
Nafcillin sodium 1g/vial, 2g/vial, 10g/vial; pwd for deep IM inj after reconstitution, IV inj or IV drip after reconstitution and dilution.
Various generic manufacturers
Indications for Nafcillin Inj:
Susceptible infections due to penicillinase-producing staphylococci.
Give by deep IM gluteal inj, or IV inj over 5–10 mins, or short-term IV drip for 24–48 hours. IM: 500mg every 4–6 hours. IV: 500mg every 4 hours. Severe infections: 1g IM or IV every 4 hours; treat for at least 14 days, then continue for at least 48 hours after becoming afebrile, asymptomatic, or (–) cultures. Endocarditis or osteomyelitis: may need longer therapy; see literature. Switch to oral therapy as soon as clinically indicated.
Give by deep IM gluteal inj only. Neonates: 10mg/kg twice daily. Infants and children <40kg: 25mg/kg twice daily.
Cephalosporin or other allergy: not recommended. Asthma. Renal impairment: consider dose reduction. Do CBCs, BUN, urinalysis, creatinine levels prior to and weekly during therapy. Monitor renal, hepatic and hematopoietic function in prolonged use. Elderly (esp. IV route). Newborns (monitor). Pregnancy (Cat.B). Nursing mothers.
May be antagonized by tetracycline; avoid. Potentiated by probenecid.
Inj site reactions, rash, serum sickness, GI upset, anaphylaxis, neuropathy, nephropathy, blood dyscrasias.
Formerly known under the brand names Nallpen, Unipen.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|